1.	Reduced Intensity Transplant Using Extracorporeal Photopheresis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Pharmaceutical / Industry Protocol IDs: ECP RIT, NCT00179790
2.	Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: BMT 0499 Solid, NCT00179816
3.	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AVF4761s, 200911736, NCT01106872
4.	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452
5.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
6.	Aerosol IL-2 for Pulmonary Metastases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2010-0700, NCT01590069
7.	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
8.	Radiation Therapy to Treat Musculoskeletal Tumors Phase: Phase II Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: RTSARC, NCT00186992
9.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
10.	Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 30 and under Sponsor: NCI, Other Protocol IDs: 05-326, Other, NCT00592293
11.	MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000680512, COG-ADVL0921, ADVL0921, NCT01154816
12.	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: NCI-2011-02605, ACNS0821, U10CA098543, COG-ACNS0821, NCT01217437
13.	Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 21 Sponsor: Other Protocol IDs: 11-183, NCT01492673
14.	A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 0 to 40 Sponsor: Other Protocol IDs: J12106, NCT01804634
15.	Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 2 to 25 Sponsor: NCI, Other Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
16.	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Phase: Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
17.	Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03112, 050909, U01CA132194, CINJ-050801, 050801, 0220080281, NCT00813423
18.	A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias Phase: Phase I Type: Treatment Status: Active Age: 4 to 35 Sponsor: NCI Protocol IDs: 110073, 11-C-0073, NCT01287104
19.	Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: NCI Protocol IDs: 080007, 08-C-0007, NCT01445379
20.	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
21.	A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Phase: Phase I Type: Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: RADIANT, NCT01625351
22.	Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01165, 12-083, U01CA069856, NCT01643278
23.	Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 100 Sponsor: Other Protocol IDs: EPROST-20110462, NCT01803152
24.	Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000554417, JHOC-J0685, NA_00003073, J0685, NCT00499733
25.	Auto Transplant for High Risk or Relapsed Solid Tumor Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569